2137 — Brii Biosciences Share News
0.000.00%
Last trade - 00:00- HK$645.88m
- -HK$1.49bn
- CNY18.61m
China's Brii Biosciences interim net loss narrows on lower R&D expenses
Brief: Brii Biosciences Announces Share Buy-Back Programme No More Than HK$60 Million
Brief: Brii Biosciences Says Arbitration Between Brii And Vir Remains In Early Stages With No Resolution
Brief: Brii Biosciences Submits Demand For Arbitration Against VIR
Brief: Brii Biosciences Posts Loss For Year Was Rmb224.1 Million
Brief: Brii Biosciences And OpenBench Announce AI-Driven Collaboration For Proprietary Technology Platform
Brief: Brii Biosciences Says HY Loss For Period Was RMB148.8 Million
Brief: Brii Biosciences Says Joincare To Obtain Exclusive License From Unit
Brief: Brii Biosciences Says Loss For Year Was RMB512.4 Million
Brief: Brii Bio Announces Signing Of Asset Purchase Agreements
Brief: Brii Biosciences Posts HY Loss RMB283.2 Million
Brief: Brii Biosciences Says On July 30, VBI Vaccines Initiated Restructuring Proceedings
Brief: Brii Bio Presents New Data From Its Ongoing Phase 2 Chronic Hepatitis B Trials
Brief: Brii Biosciences Says NMPA Of China Granted Breakthrough Therapy Designations For Brii-877 And Brii-835
Brief: Brii Biosciences Posts FY Revenue RMB617,000
VBI Vaccines rises on new license agreement
Brief: Brii Biosciences To Buy All Rights In And To Any Intellectual Property Related To Brii-179
Brief: Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure At AASLD's The Liver Meeting 2023
China's Brii Biosciences rises on progress of HBV therapy